NCT06876649 2026-03-02A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) PirtobrutinibEli Lilly and CompanyPhase 4 Recruiting787 enrolled
NCT06876662 2026-03-02A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin LymphomaEli Lilly and CompanyPhase 4 Recruiting279 enrolled